US EditionFDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body
- The FDA has authorized the use of Zoryve 0.3% topical foam as a treatment for plaque psoriasis affecting the scalp and body in patients aged 12 years and older.
- The approval was supported by findings from the ARRECTOR study, a phase 3 clinical trial, and Trial 204, a phase 2 study, which together enrolled 736 patients who received either Zoryve foam or a placebo once daily for eight weeks.
- Results from the ARRECTOR study showed that nearly two-thirds of participants receiving Zoryve achieved clearance of scalp psoriasis, while Trial 204 reported that 39.0% of patients attained clear or almost clear status on the body with at least a two-point improvement.
- Jennifer Soung, M.D., who leads clinical research at Southern California Dermatology, noted that with Zoryve foam, individuals can manage psoriasis across their entire body using a single prescription.
- Zoryve foam offers a once-daily, steroid-free topical treatment option that demonstrated effective plaque clearance and rapid itch relief in trials, supporting its use for scalp and body psoriasis.
27 Articles
27 Articles
US FDA approves Alcon’s new dry-eye drug
(Reuters) -Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED). Spun off from Novartis in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of 2025 and beyond. The approval was based on late-stage studies in which the liquid medication, Tryptyr, demonstrated natural tear production as early as day one. The company sai…
FDA approves topical foam for plaque psoriasis of the scalp and body
The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.
FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body
TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of…
Coverage Details
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
